ICER Announces Positive Early Results in Draft Evidence Report for Two Myasthenia Graves Therapies

The Institute for Clinical and Economic Review (ICER) has published its Draft Evidence Report on two drugs, eculizumaband efgartigimod, used in treating autoimmune disease Myasthenia Gravis (MG). Early conclusions are positive regarding the two drugs’ efficacy profiles. The deadline for public comments is August 18^th, 2021.

According to the report’s authors, “In conclusion, both eculizumab and efgartigimod significantly improve function and quality of life for patients with gMG. However, at the current price for eculizumab the estimated cost- effectiveness is well above typical thresholds; the cost-effectiveness of efgartigimod will depend on its actual price.” Read more here.

(Source: ICER, 7/22/21)